Provided by Tiger Trade Technology Pte. Ltd.

Mira Pharma

0.7593
+0.03975.52%
Post-market: 0.77690.0176+2.32%17:43 EDT
Volume:130.09K
Turnover:97.12K
Market Cap:31.80M
PE:-0.55
High:0.7599
Open:0.7300
Low:0.7222
Close:0.7196
52wk High:2.45
52wk Low:0.6000
Shares:41.88M
Float Shares:34.94M
Volume Ratio:1.15
T/O Rate:0.37%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.3802
EPS(LYR):-1.3505
ROE:-217.12%
ROA:-129.55%
PB:3.90
PE(LYR):-0.56

Loading ...

Mira Pharmaceuticals Announces Annual Shareholder Meeting

Reuters
·
Jul 29

Mira Pharmaceuticals Oral Form Shows 'Positive' Results in Pre-Clinical Studies

MT Newswires Live
·
Jul 10

Mira Pharmaceuticals - Announces Positive Preclinical Results for Oral Mira-55 - SEC Filing

THOMSON REUTERS
·
Jul 10

Mira Pharmaceuticals Announces Release of Mira-55 Oral Formulation Update

Reuters
·
Jul 10

MIRA Reports Positive Preclinical Data for SKNY-1 Program

TIPRANKS
·
Jul 06

Mira Pharmaceuticals reports SKNY-1 formulation results

TIPRANKS
·
Jul 06

Mira Pharmaceuticals - Announces Positive Preclinical Results for Oral Skny-1 - SEC Filing

THOMSON REUTERS
·
Jul 06

Mira Pharmaceuticals - Skny-1 Shows Favorable Bioavailability, Robust Brain and Liver Exposure, Once-daily Dosing Potential - SEC Filing

THOMSON REUTERS
·
Jul 06

Mira Pharmaceuticals Reports Positive Preclinical Oral Formulation Results for Obesity, Addiction Drug Candidate Skny-1

Reuters
·
Jul 06

Mira Pharma Reports Preclinical Study Showing Mira-55 Reduces Anxiety-like Behavior, Differs from THC Mechanism

Reuters
·
Jun 25

Mira Pharmaceuticals - Submits Phase 2a Clinical Trial Protocol to FDA for Ketamir-2 - SEC Filing

THOMSON REUTERS
·
Jun 17

Mira Pharmaceuticals submits FDA Phase 2a trial protocol for Ketamir-2 in chemotherapy-induced neuropathy

Reuters
·
Jun 17

Mira Pharmaceuticals CFO Andriy Mushak files initial beneficial ownership statement

Reuters
·
Jun 10

MIRA Pharmaceuticals Appoints New Fractional Chief Financial Officer

TIPRANKS
·
Jun 09

BRIEF-Mira Pharmaceuticals - Alan Weichselbaum To Step Down As CFO Effective June 6, 2026 - SEC Filing

Reuters
·
Jun 09

Mira Pharmaceuticals names Andriy Mushak fractional CFO, replacing Alan Weichselbaum

Reuters
·
Jun 09

MIRA Pharmaceuticals Secures Unified Global Rights to Pipeline

TIPRANKS
·
Jun 04

Mira Pharmaceuticals Inc: Controls Global Development Rights Across Entire Pipeline

THOMSON REUTERS
·
Jun 04

Mira Pharmaceuticals secures worldwide exclusive rights to MIRA-55 and SKNY-1 in amended license deal

Reuters
·
Jun 04

MIRA Expands Global Ketamir-2 License for Clinical Development

TIPRANKS
·
May 27